๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Refractory Solid Tumor

IMA402 T Cell-Engaging Receptor Molecule (TCERยฎ) in Recurrent and/or Refractory Solid Tumors NCT05958121Phase 1, Phase 229 sites๐Ÿ“ Heidelberg๐Ÿ“ Heidelberg๐Ÿ“ Mannheim Immatics Biotechnologies GmbH ยท Tests: IMA402, IMA402 and checkpoint inhibitor, IMA402 and chemotherapy, IMA402 and IMA401, IMA402 and monoclonal antibody TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies NCT06484816Phase 11 site๐Ÿ“ Hangzhou Shenzhen TargetRx Co., Ltd. ยท Tests: TGRX-1942 Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors NCT02508038Phase 11 site๐Ÿ“ Madison University of Wisconsin, Madison ยท Tests: TCRฮฑฮฒ+/CD19+ depleted Haploidentical HSCT, Zoledronate A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. NCT07389239Phase 1, Phase 21 site๐Ÿ“ Chicago University of Chicago ยท Tests: Decitabine, Cyclophosphamide Conditioning, NY-ESO-1 TCR/ dnTGFฮฒRII, Aldesleukin Study of GV20-0251 in Participants With Solid Tumor Malignancies NCT07070518Phase 1, Phase 23 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Shanghai GV20 Therapeutics ยท Tests: GV20-0251 LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours. NCT06193902Phase 1, Phase 22 sites๐Ÿ“ London๐Ÿ“ Manchester Leucid Bio ยท Tests: LEU011 A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPฮฑ-CD47 Pathway, in Solid or Hematological Tumors NCT05892718Phase 18 sites๐Ÿ“ Port Saint Lucie๐Ÿ“ Huntersville๐Ÿ“ Greenville FBD Biologics Limited ยท Tests: HCB101 Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors NCT07145255Phase 1, Phase 27 sites๐Ÿ“ San Francisco๐Ÿ“ Grand Rapids๐Ÿ“ East Brunswick MBrace Therapeutics ยท Tests: ADC Study in Children and Adolescents of 177Lu-DOTATATE (Lutatheraยฎ) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). NCT06607692Phase 1, Phase 21 site๐Ÿ“ Boadilla del Monte Fundaciรณn de investigaciรณn HM ยท Tests: Olaparib; 177Lu-DOTATATE Trial of DFP-14927 in Advanced Solid Tumors NCT03943004Phase 12 sites๐Ÿ“ Los Angeles๐Ÿ“ Houston Delta-Fly Pharma, Inc. ยท Tests: DFP-14927 Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors NCT04803318Phase 21 site๐Ÿ“ Guangzhou Second Affiliated Hospital of Guangzhou Medical University ยท Tests: Combination of three inhibitors Trametinib, Everolimus and Lenvatinib Clinical Efficacy of Tumour Treatment Vaccine (TTV) Combined With PD-1 in the Treatment of Relapsed Refractory Advanced Solid Tumours NCT06430502NA1 site๐Ÿ“ Wuxi Wuxi People's Hospital ยท Tests: Tumor Treatment Vaccine; PD-1/L1 inhibitors A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors NCT04794972Phase 16 sites๐Ÿ“ Beijing๐Ÿ“ Chongqing๐Ÿ“ Guangzhou Sichuan Baili Pharmaceutical Co., Ltd. ยท Tests: GNC-039 KSX01-TCRT Injection Project in Solid Tumors NCT05811975EARLY Phase 11 site๐Ÿ“ Nanning TCRx Therapeutics Co.Ltd ยท Tests: KSX01-TCRT injection Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: Becotatug Vedotin Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors NCT06132503Phase 11 site๐Ÿ“ West Valley City Lantern Pharma Inc. ยท Tests: LP-284 JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma NCT07603479Phase 11 site๐Ÿ“ Beijing Jecho Biopharmaceuticals Co., Ltd. ยท Tests: JL19001, subcutaneous injection, 1 ฮผg/kg, JL19001, subcutaneous injection, 5 ฮผg/kg, JL19001, subcutaneous injection,10 โ€ฆ APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors NCT05701306Phase 1, Phase 23 sites๐Ÿ“ Guangzhou๐Ÿ“ Wuhan๐Ÿ“ Tianjin Ascentage Pharma Group Inc. ยท Tests: APG-115, APG-2575 A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies NCT05669430Phase 1, Phase 213 sites๐Ÿ“ Los Angeles๐Ÿ“ Denver๐Ÿ“ New Haven GV20 Therapeutics ยท Tests: GV20-0251, GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDAยฎ], GV20-0251 and Pembrolizumab [KEYTRUDAยฎ] Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites๐Ÿ“ Phoenix๐Ÿ“ Tucson๐Ÿ“ Los Angeles Genmab ยท Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin Clinical Evaluation of 177Lu-AB-3PRGD2 in Various Solid Tumors With Integrin ฮฑvฮฒ3 Positive Expression NCT06375564Phase 11 site๐Ÿ“ Xiamen The First Affiliated Hospital of Xiamen University ยท Tests: 177Lu-AB-3PRGD2 radioligand therapy Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors NCT06014658Phase 1, Phase 217 sites๐Ÿ“ San Francisco๐Ÿ“ Aurora๐Ÿ“ Atlanta MBrace Therapeutics ยท Tests: Antibody-Drug Conjugate GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors NCT06265025Phase 1, Phase 24 sites๐Ÿ“ Goyang-si๐Ÿ“ Seoul๐Ÿ“ Seoul GeneMedicine Co., Ltd. ยท Tests: GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C) Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma NCT07598955Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: Cyclophosphamide, Fludarabine, EB-CAR30-NK, EB-CAR5-NK, EB-CARMSLN-NK Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies NCT07309770Phase 21 site๐Ÿ“ Shanghai Sheng Zhang ยท Tests: SHR-A1811, Trastuzumab Rezetecan Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors NCT06320405Phase 1, Phase 21 site๐Ÿ“ Portland OHSU Knight Cancer Institute ยท Tests: Axatilimab, Biopsy, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging Evaluation of XYA02 in Patients With Advanced Solid Tumors NCT07670312Phase 1, Phase 25 sites๐Ÿ“ Sydney๐Ÿ“ Sydney๐Ÿ“ Melbourne XYone Therapeutics, Inc ยท Tests: XYA02 TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors NCT07713732Phase 13 sites๐Ÿ“ Camperdown๐Ÿ“ Malvern๐Ÿ“ Nedlands Treeline Biosciences, Inc. ยท Tests: TLN-499, Venetoclax A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies NCT04678648Phase 13 sites๐Ÿ“ Los Angeles๐Ÿ“ Denver๐Ÿ“ Nashville RasCal Therapeutics, Inc. ยท Tests: RSC-1255 Dose Escalation, RSC-1255 Dose Expansion Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors NCT05608148Phase 11 site๐Ÿ“ Fukuoka Kyushu University ยท Tests: Biological, Biological, Biological, Biological
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy